| Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study.Gastric Cancer | PMID 34480657PMC8732926 | 2022-Jan | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics.Eur J Haematol | PMID 34496096PMC9293199 | 2022-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Respir Med | PMID 34506761无 PMCID | 2022-Jan | 0.95 | The study is a randomized Phase III trial of cyclophosphamide for idiopathic pulmonary fibrosis (a non-malignant condition), not an oncology trial. While it has a drug intervention and primary results, it fails the core oncology criterion. The primary endpoint (3-month mortality) is not a standard time-to-event efficacy endpoint as defined (OS, PFS, DFS, EFS, RFS, TTP, or KM/HR). | 待处理 |
| Japanese cedar pollen sublingual immunotherapy is effective in treating seasonal allergic rhinitis during the pollen dispersal period for Japanese cedar and Japanese cypress.Allergol Int | PMID 34509370无 PMCID | 2022-Jan | 0.99 | 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 | 待处理 |
| Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.Diabetes Obes Metab | PMID 34514682PMC9293236 | 2022-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104-week extension to a 52-week randomized, phase 3 study and liver fat MRI substudy.Diabetes Obes Metab | PMID 34514692PMC9293136 | 2022-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial.Lancet Infect Dis | PMID 34529962PMC7613317 | 2022-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial.Lancet Infect Dis | PMID 34529963PMC7613326 | 2022-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Randomized Controlled Trial of a Dichoptic Digital Therapeutic for Amblyopia.Ophthalmology | PMID 34534556无 PMCID | 2022-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a phase 3 randomised controlled trial.Lancet Infect Dis | PMID 34563277无 PMCID | 2022-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy of mirabegron, a β3 -adrenoreceptor agonist, in Japanese women with overactive bladder and either urgency urinary incontinence or mixed urinary incontinence: Post-hoc analysis of pooled data from two randomized, placebo-controlled, double-blind studies.Int J Urol | PMID 34605079PMC9293404 | 2022-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Added Value of a Blinded Outcome Adjudication Committee in an Open-Label Randomized Stroke Trial.Stroke | PMID 34607469PMC8700318 | 2022-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer.Ann Oncol | PMID 34624497无 PMCID | 2022-Jan | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.Breast Cancer | PMID 34661821PMC8732856 | 2022-Jan | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Predictive value of EGFR mutation in non-small-cell lung cancer patients treated with platinum doublet postoperative chemotherapy.Cancer Sci | PMID 34689382PMC8748214 | 2022-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150.Br J Cancer | PMID 34711947PMC8727569 | 2022-Jan | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study.Liver Int | PMID 34717041PMC9299194 | 2022-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Association of Baseline Patient-reported Health-related Quality of Life Metrics with Outcome in Localised Prostate Cancer.Clin Oncol (R Coll Radiol) | PMID 34728131无 PMCID | 2022-Jan | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial.J Am Soc Nephrol | PMID 34732509PMC8763180 | 2022-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| LDL-C calculated by Friedewald, Martin-Hopkins, or NIH equation 2 versus beta-quantification: pooled alirocumab trials.J Lipid Res | PMID 34774485PMC8953656 | 2022-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Does variability in automated perfusion software outputs for acute ischemic stroke matter? Reanalysis of EXTEND perfusion imaging.CNS Neurosci Ther | PMID 34786868PMC8673699 | 2022-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.Lancet Gastroenterol Hepatol | PMID 34798036无 PMCID | 2022-Jan | 0.95 | The study is a Phase III randomized controlled trial of a drug (etrolizumab) for ulcerative colitis, which is not a cancer (malignant neoplasm). Therefore, it is excluded based on the non-oncology criterion, regardless of other meeting criteria. | 待处理 |
| Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.Lancet Gastroenterol Hepatol | PMID 34798037无 PMCID | 2022-Jan | 0.95 | The study is a Phase III randomized controlled trial for a drug intervention in ulcerative colitis, which is not a human malignant neoplasm (oncology) condition. Furthermore, the primary efficacy endpoint is remission at week 62 (a binary outcome), not a time-to-event endpoint such as overall survival, progression-free survival, or disease-free survival analyzed via Kaplan-Meier methods or hazard ratios. | 待处理 |
| Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study.Int J Clin Oncol | PMID 34800178PMC8732816 | 2022-Jan | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer.Eur J Cancer | PMID 34801353无 PMCID | 2022-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Tolerability and safety of galcanezumab in patients with chronic cluster headache with up to 15 months of galcanezumab treatment.Headache | PMID 34806783PMC9299588 | 2022-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study.Adv Ther | PMID 34816373PMC8799567 | 2022-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The radiotherapy quality assurance gap among phase III cancer clinical trials.Radiother Oncol | PMID 34838891PMC8900671 | 2022-Jan | 0.95 | The report is an analysis of radiotherapy quality assurance practices across phase III oncology trials. It does not present efficacy results of a specific drug-containing intervention trial with a primary/key secondary time-to-event endpoint (OS, PFS, etc.). It is a methodological review of QA across multiple trials, not an original result report of a single randomized trial with a drug intervention and a survival endpoint. | 待处理 |
| How bilastine is used to treat allergic rhinitis and urticaria in children.Immunotherapy | PMID 34850647无 PMCID | 2022-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of co-administered ivermectin and albendazole in school-aged children and adults infected with Trichuris trichiura in Côte d'Ivoire, Laos, and Pemba Island, Tanzania: a double-blind, parallel-group, phase 3, randomised controlled trial.Lancet Infect Dis | PMID 34856181无 PMCID | 2022-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.Lancet Oncol | PMID 34871550无 PMCID | 2022-Jan | 0.96 | 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 | 待处理 |
| Endovascular Thrombectomy in Young Patients With Stroke: A MR CLEAN Registry Study.Stroke | PMID 34872339无 PMCID | 2022-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.Lancet Oncol | PMID 34914889无 PMCID | 2022-Jan | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |
| Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial.Lancet Oncol | PMID 34919827无 PMCID | 2022-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study.Cancer Med | PMID 34921525PMC8729061 | 2022-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and cost-effectiveness of task-shared care for people with severe mental disorders in Ethiopia (TaSCS): a single-blind, randomised, controlled, phase 3 non-inferiority trial.Lancet Psychiatry | PMID 34921796PMC8872807 | 2022-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability.Drug Saf | PMID 34928484PMC8763844 | 2022-Jan | 0.96 | 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 | 待处理 |
| Health-related Quality of Life in Intermediate- or High-risk Patients Treated With Radical External Radiotherapy and Adjuvant Docetaxel for Localized Prostate Cancer: A Randomized, Phase III SPCG-13 Study.Anticancer Res | PMID 34969712无 PMCID | 2022-Jan | 0.95 | The record is a Phase III randomized controlled trial in oncology, but it reports only health-related quality of life outcomes, not the required survival, progression, recurrence, death, hazard, or time-to-event efficacy outcomes. | 待处理 |
| Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial.Lancet Haematol | PMID 34971577无 PMCID | 2022-Jan | 0.45 | The study is a Phase III randomized trial of a drug for acute graft-versus-host disease (GVHD) following HSCT for hematological malignancy. However, the primary efficacy endpoint is Overall Response Rate (ORR) at day 28, which is a binary outcome, not a time-to-event endpoint like OS, PFS, DFS, etc. No time-to-event endpoints are reported or mentioned in the abstract. Therefore, it does not meet the core requirement for a time-to-event efficacy endpoint. | 待处理 |
| Hydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trial.Lancet Haematol | PMID 34971579PMC10072240 | 2022-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trials.Lancet Haematol | PMID 34971581PMC9098160 | 2022-Jan | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial.Nat Med | PMID 35013615PMC9406237 | 2022-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Pyronaridine-artesunate or dihydroartemisinin-piperaquine combined with single low-dose primaquine to prevent Plasmodium falciparum malaria transmission in Ouélessébougou, Mali: a four-arm, single-blind, phase 2/3, randomised trial.Lancet Microbe | PMID 35028628PMC8721154 | 2022-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary.J Immunother Cancer | PMID 35074904PMC8788316 | 2022-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| The Effect of Acid Suppression Therapy on the Safety and Efficacy of Plecanatide: Analysis of Randomized Phase III Trials.Clin Ther | PMID 35086735无 PMCID | 2022-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy.J Immunother Cancer | PMID 35101942PMC8804705 | 2022-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study.BioDrugs | PMID 35133617PMC8847243 | 2022-Jan | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Quantifying the relationship between disability progression and quality of life in patients treated for NMOSD: Insights from the SAkura studies.Mult Scler Relat Disord | PMID 35158426无 PMCID | 2022-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Triamcinolone Acetonide in the Treatment of Perennial Allergic Rhinitis: A post hoc Analysis of Quality of Life during a Phase III Study.Int Arch Allergy Immunol | PMID 34515149PMC8985020 | 2022 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Triamcinolone Acetonide in the Treatment of Perennial Allergic Rhinitis: A post hoc Efficacy Analysis of a Phase III Study Performed in Russia.Int Arch Allergy Immunol | PMID 34535609PMC8984997 | 2022 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |